GH Research PLC (GHRS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

GH Research PLC (GHRS) closed at USD 18.56 on 2026-10-14, a change of +32.6 % over the past year, with a market capitalization of USD 1.29B.

GH Research PLC recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

GH Research PLC key figures

Previous close

USD 18.56 (2026-10-14)

1-year change

+32.6 %

Market cap

USD 1.29B

Enterprise value

USD 928.87M

P/E ratio (trailing)

-19.00

P/E ratio (forward)

-10.17

EPS (trailing)

-0.99

EPS (forward)

-1.85

PEG ratio

n/a

Price to book

3.59

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.48

Employees

73

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About GH Research PLC

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for GH Research PLC and compare it with other stocks.